




Searching News Database: TORISEL
HSMN NewsFeed - 26 Apr 2017
Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
HSMN NewsFeed - 28 Jan 2013
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
HSMN NewsFeed - 13 Dec 2012
A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer
A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 20 Feb 2008
New Breakthrough Treatment for Advanced Kidney Cancer Shows 49 Per Cent Higher Survival Rates
New Breakthrough Treatment for Advanced Kidney Cancer Shows 49 Per Cent Higher Survival Rates
HSMN NewsFeed - 26 Nov 2007
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
HSMN NewsFeed - 30 May 2007
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
HSMN NewsFeed - 6 Oct 2006
Wyeth Submits NDA and MAA for Torisel for the Treatment of Advanced Renal Cell Carcinoma
Wyeth Submits NDA and MAA for Torisel for the Treatment of Advanced Renal Cell Carcinoma